Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 04:55am CEST

THOUSAND OAKS, Calif., April 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that George Rathmann, founding CEO of Amgen from 1980 to 1988 and board chairman until 1990, has passed away.

Recruited by Bill Bowes, one of Amgen's founders, Rathmann possessed the kind of passion and charisma that helped build the company and attract world-class scientific talent. Regarded as one of the founding fathers of biotechnology, George had the vision to see how biotechnology could transform the practice of medicine with the mix of business and science to bring that vision to life. One of Rathmann's chief accomplishments was finding the funds Amgen needed during its start-up years. Nicknamed the "Golden Throat" by friends who admired his persuasiveness, he secured venture capital, built revenue streams through partnerships, and guided Amgen through its first public offerings.

"George Rathmann was a biotechnology giant and we were privileged to have him as our first CEO. George's vision and values are as alive today at Amgen as they were when he led the Company," said Kevin Sharer, Chairman and CEO of Amgen. "Bob Bradway, our next CEO, and I both share George's commitment to patients and conviction that being science-based is the best foundation for innovation in biotechnology."

Through the years, Amgen has continued to recognize the significant impact Rathmann made on the Company. In 2004, a full-size sculpture of Rathmann was dedicated on Amgen's campus in recognition of his leadership. In 2005, Amgen created the annual George B. Rathmann Award, the company's highest honor, to recognize staff members who exemplify Amgen's standards of excellence to advance Amgen's mission to serve patients.

Rathmann was recognized as BIO's CEO of the year in 1987 and 1988. Upon leaving Amgen, Rathmann became CEO and chairman of Seattle-based biotech ICOS Corporation (later acquired by Eli Lilly). He later served as CEO and chairman of genomics company Hyseq, Inc.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

SOURCE Amgen

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
10:59p AMGEN INC : Entry into a Material Definitive Agreement, Financial Statements and..
07:27p AMGEN : Health and Human Services Department (HHS); Food and Drug Administration..
01:14p CELGENE CORPORATION (NASDAQ : CELG) Cambridge Expansion Drive Gathers Momentum
04/21 AMGEN : Announces Webcast Of 2017 First Quarter Financial Results
04/18 AMGEN : Launches Neulasta® (pegfilgrastim) Onpro® NARRATIVES
04/06 AMGEN, INC. (NASDAQ : AMGN) Submits sBLA Seeking To Expand XGEVA Label
04/06 AMGEN : Files for Xgeva Label Expansion, To Include Myeloma
04/05 APPLICATION FOR MULTIPLE INDICATIONS : AMGN) To US And Europe Regulators
04/04 AMGEN, INC. (NASDAQ : AMGN) To Move Employees From Headquarters In Restructuring..
04/04 AMGEN : Submits Applications In The US And Europe To Expand Current Indication F..
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03:23p My 83 Stock Portfolio Review Highlighting Defensive Sectors And My Energy Sto..
11:35a BIOTECH FORUM DAILY DIGEST : Biotech Lags; Revisiting Radius Health
10:50a A Physician Analyzes Valeant's Siliq, As The Stock Crashes
09:05a Wolfe Research names favorite large-cap longs and shorts
07:22a Celgene And Biogen Earnings Could Make Or Break The Biotech Sector